This disclosure relates to a method and a system for processing grapes. An example system includes a simulated moving bed (SMB) device configured to receive a feed stream and an eluent stream as inputs and provide an extract stream and a raffinate stream as outputs. The feed stream includes a grape juice, the extract stream includes a high-sugar grape juice, and the raffinate stream includes a low-sugar grape juice. The system also includes fermentation equipment configured to produce a low-alcohol wine from the low-sugar grape juice.

A system for the treatment of a liquid plastic-derived oil having a pretreating section that includes a pretreating system having one or more reactors that may receive the liquid plastic-derived oil having one or more contaminants and a first contamination level. The one or more reactors includes a sorbent material having a faujasite (FAU) crystal framework type zeolitic molecular sieve and that may remove a first portion of the one or more contaminants from the liquid plastic-derived oil and generate a treated liquid plastic-derived oil having a second contamination level that is less than the first contamination level. The liquid plastic-derived oil is derived from a solid plastic waste (SPW), and the first portion of the one or more contaminants includes a halogen.

A purification system for separating a molecule of interest from a solution is provided and generally includes a plurality of resin processing sections, wherein each of the resin processing sections is controllably separated from each other via a configurable valve, wherein the configurable valve is configured to introduce or evacuate a fluid/resin into/out of a proximately located processing section, a plurality of inlets configured to introduce fluid and/or resin into one or more of the plurality of resin processing sections.

The present invention relates to a method of preparing kestose-containing fructooligosaccharide, and more specifically, a method of preparing kestose-containing fructooligosaccharide having a high content of kestose and excellent storage stability.

A high salinity wastewater treatment system is provided according to the present application, which includes a hydrogel loading system and a flow-storage different-oriented-inlet-and-outlet system. The hydrogel loading system includes six separation plates, a wastewater treatment area, a water distribution bin, a rotating shaft, a driving motor and a fixed bracket. The six separation plates evenly separate the wastewater treatment area into six separate treatment sectors in an axial direction. The six separate treatment sectors are filled with hydrogel materials with water purification effect. The high salinity wastewater infiltrates into each separate treatment sector one by one through high salinity wastewater inlet meshes on a surface of the wastewater treatment area, and the purified high salinity wastewater is discharged through a wastewater cleaning outlet pipe with a same water inlet direction as a cleaning filler distribution pipe.

A high salinity wastewater treatment system is provided according to the present application, which includes a hydrogel loading system and a flow-storage different-oriented-inlet-and-outlet system. The hydrogel loading system includes six separation plates, a wastewater treatment area, a water distribution bin, a rotating shaft, a driving motor and a fixed bracket. The six separation plates evenly separate the wastewater treatment area into six separate treatment sectors in an axial direction. The six separate treatment sectors are filled with hydrogel materials with water purification effect. The high salinity wastewater infiltrates into each separate treatment sector one by one through high salinity wastewater inlet meshes on a surface of the wastewater treatment area, and the purified high salinity wastewater is discharged through a wastewater cleaning outlet pipe with a same water inlet direction as a cleaning filler distribution pipe.

Method and system for purifying a sample comprising a biomolecule of interest and impurities, comprising expressing said biomolecule of interest in a bioreactor to form a product sample comprising said biomolecule of interest and impurities; subjecting said product sample to filtration to form a clarified product sample; subjecting said clarified product sample to affinity chromatography to remove impurities; subsequently subjecting said product sample to diafiltration followed by virus filtration and optional concentration. The buffer used during the diafiltration step (and thus in the virus filtration step) is the buffer desired for the final formulation of the product.

A parallel assembly (2; 11; 51) of chromatography column modules (3a,b,c; 13a,b,c; 53a,b,c, 90a, b) connected in a rigid housing (21; 61), the assembly having one common assembly inlet (15; 55) and one common assembly outlet (17; 57), each column module comprising a bed space (29) filled with chromatography medium and each column module comprises integrated fluid conduits which when the column module is connected with other column modules in the rigid housing are adapted to connect the bed space (29) of the column module with the assembly inlet (15; 55) and the assembly outlet (17; 57), wherein the total length and/or volume of the fluid conduit from the assembly inlet to one bed space together with the length and/or volume of the fluid conduit from the same bed space to the assembly outlet is substantially the same for all bed spaces and modules installed in the parallel assembly.

Methods are disclosed for producing highly purified recombinant human insulin (RHI) having a purity of 99.0% (w/w) or greater, a Total Impurity (not including the related substance desamido Asn.sup.A21-RHI, as specified by USP) of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less. Also disclosed are API compositions of highly purified RHI having a purity of 99.0% (w/w) or greater, a Total Impurity of 0.8% (w/w) or less, and an impurity C of 0.1% (w/w) or less.

A process for providing a mono-PEGylated protein composition is provided. The process is particularly suitable for providing mono-PEGylated erythropoietin composition. The process comprises subjecting a mixture comprising non-PEGylated, mono-PEGylated and oligo-PEGylated to a hydrophobic interaction chromatography process.